Can digital care close the GLP-1 treatment gap?
A UK observational study of more than 8,000 women found substantial six-month weight loss and high retention in a structured digital-first GLP-1 programme. It is promising implementation evidence, but not a comparison with NHS or face-to-face care.
What a six-month UK study of more than 8,000 women receiving digital-first GLP-1 treatment found — and what it cannot tell us.
The programme was delivered remotely. Participants completed eligibility assessment and biochemical monitoring, received clinician review and electronic prescribing, and had weekly video-supported follow-up alongside clinician-guided dose titration.
A new Nature Medicine study reports six-month outcomes for 8,127 UK women who began GLP-1 receptor agonist therapy through this digital programme. Almost all participants received tirzepatide. The study was observational: it describes outcomes in this service, rather than comparing the service with face-to-face care or another treatment approach.1
Weight loss at six months
Of the 7,297 women with a six-month weight measurement, the mean weight reduction was 16.1 kg. This equated to 15.5% of baseline weight (95% confidence interval 15.4% to 15.7%).
- 83.1% achieved at least 10% weight loss.
- 22.4% achieved at least 20% weight loss.
- 91.4% remained on treatment at six months.
These figures describe women who started treatment through this particular service. They should not be read as a direct comparison with NHS care, face-to-face weight-management services or other digital providers.1
Changes in blood markers
Among participants with paired measurements, mean HbA1c fell by 3.3 mmol/mol and mean LDL cholesterol fell by 0.61 mmol/L over six months. These are changes in intermediate risk markers. The study did not assess whether cardiovascular events, such as myocardial infarction or stroke, became less common.1
How treatment was delivered
Dose escalation followed licensing recommendations but was adjusted for weight trajectory and tolerability rather than occurring automatically. At six months, mean tirzepatide exposure was 9.5 mg weekly. This describes the programme’s approach; it does not establish an optimum dose or show that a lower dose will give the same outcomes in other settings.1
Side effects were reported by 62.7% of participants. No serious treatment-related adverse events were identified during the six-month follow-up. That is reassuring within this cohort, but six months is not long enough to establish longer-term safety.1
What this means for primary care
The most striking operational finding was retention: more than nine in ten participants remained on treatment at six months. The study shows that a structured, digitally enabled model with clinical review, monitoring and tailored titration can be delivered at scale in a self-pay setting.
However, it was not a randomised trial and had no comparator group. Participants paid a fixed fee for the programme, which was partly subsidised by the provider during the study period. The study did not measure GP workload, NHS costs or outcomes beyond six months. These factors limit how directly the findings can be applied to routine NHS primary care.1
The paper also declares that SheMed and eMed Healthcare UK co-operated the programme evaluated. Two authors were employees of those organisations, and several authors declared relevant financial interests.1
Reference
- Deanfield J, Wong JLC, Katsoulis M, et al. Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women. Nature Medicine. Published online 16 October 2026. doi:10.1038/s41591-026-04687-x.